Drug strategies targeting CYP51 in neglected tropical diseases - Wikidata - wikimedia - TriplyDB

Drug strategies targeting CYP51 in neglected tropical diseases

Drug strategies targeting CYP51 in neglected tropical diseases

http://www.wikidata.org/entity/Q34622554

about

Targeting Ergosterol biosynthesis in Leishmania donovani: essentiality of sterol 14 alpha-demethylase Development of a Fluorescence-based Trypanosoma cruzi CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas Disease Ravuconazole self-emulsifying delivery system: in vitro activity against Trypanosoma cruzi amastigotes and in vivo toxicity.Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51.The Effectiveness of Natural Diarylheptanoids against Trypanosoma cruzi: Cytotoxicity, Ultrastructural Alterations and Molecular Modeling Studies Synthesis and Evaluation of Oxyguanidine Analogues of the Cysteine Protease Inhibitor WRR-483 against Cruzain.Regulation of Sterol Biosynthesis in the Human Fungal Pathogen Aspergillus fumigatus: Opportunities for Therapeutic Development Rapid Chagas Disease Drug Target Discovery Using Directed Evolution in Drug-Sensitive Yeast.Targeting CYP51 for drug design by the contributions of molecular modeling.Cholesterol metabolism: a potential therapeutic target in Mycobacteria.Growth-arresting Activity of Acmella Essential Oil and its Isolated Component D-Limonene (1, 8 P-Mentha Diene) against Trichophyton rubrum (Microbial Type Culture Collection 296).CYP51 is an essential drug target for the treatment of primary amoebic meningoencephalitis (PAM).4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection.A convergent, scalable and stereoselective synthesis of azole CYP51 inhibitors.Phenotypic screening approaches for Chagas disease drug discovery.Identification of di-substituted ureas that prevent growth of trypanosomes through inhibition of translation initiation.Synthesis and Biological Activity of Sterol 14α-Demethylase and Sterol C24-Methyltransferase Inhibitors Metabolomics and lipidomics reveal perturbation of sphingolipid metabolism by a novel anti-trypanosomal 3-(oxazolo[4,5-b]pyridine-2-yl)anilide

P2860

Q28544037-2BE142F3-ED2F-4D0F-927F-657C52863FDB Q28548320-8B4ACC7F-408D-4675-A973-08CE0A4C8756 Q33713176-CA0C4235-6988-4F5E-A462-AE6E522ADDEC Q34701325-F6065241-EA49-4ED7-A8E7-AFD98F64C72F Q36141471-A686F50E-25BC-4C09-80FC-2622FB2647A7 Q36473159-630341B1-583F-42AB-9C03-EF8CA1A31629 Q37617395-EA5DD9D5-CEF7-4C72-8D96-39B20E731485 Q38782578-722B3748-68BC-4670-A425-B5927D37482F Q38917135-CFAAE99C-F84E-49BF-B386-9B82BA8C591F Q39047211-361ABB43-157B-42A2-AFCC-07F9E38C6B77 Q47162097-4555C33B-7F74-4D27-BD9B-A913FA29FF23 Q47239192-C238F43A-BE3C-4284-9CFE-B8459A3FA741 Q48342608-E79A542B-506E-4FF6-8456-4E6CA42382D3 Q49679428-9B86A8C3-2D72-47F0-939F-04B820BB5B64 Q49862753-249FF112-EA87-42B3-A858-CDA2F103452C Q51732698-70680DEC-6778-4214-A4EA-522F1301127F Q58842234-01ECFB47-E7BD-4F4A-B574-FB13EF3E0CE1 Q58852782-49B45691-02FC-4BE4-ADEE-F68BCAA90FFC

P2860

Drug strategies targeting CYP51 in neglected tropical diseases

http://www.wikidata.org/entity/Q34622554

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Drug strategies targeting CYP51 in neglected tropical diseases

@ast

Drug strategies targeting CYP51 in neglected tropical diseases

@en

Drug strategies targeting CYP51 in neglected tropical diseases

@nl

type

label

Drug strategies targeting CYP51 in neglected tropical diseases

@ast

Drug strategies targeting CYP51 in neglected tropical diseases

@en

Drug strategies targeting CYP51 in neglected tropical diseases

@nl

prefLabel

Drug strategies targeting CYP51 in neglected tropical diseases

@ast

Drug strategies targeting CYP51 in neglected tropical diseases

@en

Drug strategies targeting CYP51 in neglected tropical diseases

@nl

P1433

Q34622554-4E32D947-BBAF-4F57-9F4A-19B92BD2E134

P1476

Q34622554-790E55A5-4EE3-43AA-8228-229974BE46EF

P2093

Q34622554-114D3272-1A21-4940-8D73-5F3C6E29C742

Q34622554-5D1B6051-55B1-44F4-A5D5-9940A0AD4273

Q34622554-EC690686-3759-4107-9544-022867460CF0

P2860

Q34622554-016B5EEE-D43B-4BB6-99D9-94176AA9847D

Q34622554-02713DF9-AE44-4D4E-B72F-AEFCDDF4B631

Q34622554-02CC2CD0-4A16-492E-92BD-CB5825909B3E

Q34622554-059030DE-AD53-4643-B2EB-73FFE6600DBB

Q34622554-05A65C9C-5900-442F-982E-3D05B9FC0509

Q34622554-062F595E-E971-4759-9473-3775A2617520

Q34622554-096021B1-FAC1-454E-8145-5F761B79D17A

Q34622554-0BC3262F-E101-4B28-BC36-68870ADDA45D

Q34622554-0D60981D-133A-48B5-A27C-4CCF445D689E

Q34622554-0DAF840D-615B-4DDC-9690-4E21D6039236

P304

Q34622554-978C9B40-EB01-40B6-9722-1D812224BF65

P31

Q34622554-747598E0-5A58-4D82-8C7B-6A5F5ADA5A56

Q34622554-FE750112-95B8-4EFD-843D-5589C9367C54

P356

Q34622554-D11FA6F3-9B95-418D-9CA3-292B5130E5F9

P433

Q34622554-83BE5F39-F343-4B46-A519-6FA69747F30D

P478

Q34622554-672BDF31-5D51-490F-A584-BFAE474A027E

P577

Q34622554-46011FF9-8A7E-4BB7-9564-09F466DAC8A3

Q34622554-80FEADF5-2493-45CE-BDC8-3EEFB04C3168

P5875

Q34622554-3F82AA6F-F5E0-49FB-ABBF-454368A66ECE

P698

Q34622554-252BAE5C-51BC-4EBC-AB71-FAD5A2BCC542

P921

Q34622554-11C3FE0D-9C0E-4749-961D-B009F555FD9C

Q34622554-6BFDAEEB-7A5F-4BAB-9656-C9DBDFC19372

P932

Q34622554-57A183A8-45FB-459E-B4F7-17EFF7B28289

P356

P1433

Chemical Reviews

P1476

Drug strategies targeting CYP51 in neglected tropical diseases

@en

P2093

Jun Yong Choi

http://www.w3.org/2001/XMLSchema#string

Larissa M Podust

http://www.w3.org/2001/XMLSchema#string

William R Roush

http://www.w3.org/2001/XMLSchema#string

P2860

Interventions for American cutaneous and mucocutaneous leishmaniasis

Structural basis of human CYP51 inhibition by antifungal azoles

Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases

Induction of resistance to azole drugs in Trypanosoma cruzi.

Ultrastructural and biochemical alterations induced by 22,26-azasterol, a delta(24(25))-sterol methyltransferase inhibitor, on promastigote and amastigote forms of Leishmania amazonensis.

Current and emerging azole antifungal agents

VNI cures acute and chronic experimental Chagas disease

CYP51 structures and structure-based development of novel, pathogen-specific inhibitory scaffolds

Phylogenetic and biochemical evidence for sterol synthesis in the bacterium Gemmata obscuriglobus

Crystal structures of Trypanosoma brucei sterol 14alpha-demethylase and implications for selective treatment of human infections

P304

11242-11271

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/CR5003134

http://www.w3.org/2001/XMLSchema#string

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

114

http://www.w3.org/2001/XMLSchema#string

P577

2014-10-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2014-11-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

267758732

http://www.w3.org/2001/XMLSchema#string

P698

25337991

http://www.w3.org/2001/XMLSchema#string

P921

hormone antagonist

mechanism of action

P932

4254036

http://www.w3.org/2001/XMLSchema#string